0810010067/J591; A Randomized Phase II Trial of 177-Lu Radio-labeled Monoclonal Antibody HuJ591 (177-Lu-J591) with Ketoconazole in Patients with High-Risk Castrate Biochemically Relapsed Prostate Cancer after Local Therapy
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Prostate Cancer
Age: Between 18 - 100 Years
Histologically or cytologically confirmed adenocarcinoma of the prostate previously treated with surgery and/or radiotherapy
Biochemical progression (rising PSA) after medical or surgical castration
High risk of systemic progression
Use of red blood cell or platelet transfusions within 4 weeks of treatment
Use of hematopoietic growth factors within 4 weeks of treatment
Active serious infection
History of deep vein thrombosis and/or pulmonary embolus within 3 months of study entry
Known history of HIV.
Currently active other malignancy other than non-melanoma skin cancer.
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required